Trypanosomiasis, African Clinical Trial
Official title:
Screen and Treat Implementation in Insecure Areas With Limited Capacities for HAT Control
Verified date | January 2024 |
Source | Institute of Tropical Medicine, Belgium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Human African Trypanosomiasis (HAT), or sleeping sickness, is one of the parasitic diseases targeted for interruption of transmission by 2030 by the WHO. The development of fexinidazole as treatment is a huge step towards this achievement; however, the diagnostic algorithm remains complex due to limited sensitivity and specificity of the available tests. A combination of serological screening and confirmation of infection through parasite visualization remains the preferred strategy, although it can be difficult to ensure its full performance in areas that are hard to reach or have limited access to electricity and other means. The present study would like to test an approach of ensuring treatment with fexinidazole of sero-suspects without confirmation of disease, among patients that consult fixed health infrastructures in the provinces of Maniema, Lomami and Tanganyika. This should enable access to gHAT treatment for patients living in hard to reach areas, actively seeking health care.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 30, 2024 |
Est. primary completion date | January 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility | Inclusion Criteria: - Show any suggestive symptoms of gHAT, such as headache (>14 days), long-term fever unless other obvious cause(s), malaise, weakness, arthralgia, facial edema, pruritus, lymphadenopathy, weight loss, mental confussion, abnormal behavior, logorrhea, speech impairment, anxiety, tremor, motor weakness, ataxia, abnormal gait, abnormal movements or seizures; - Being older than 6 years old and weighing at least 20 kg; - Willing and able to provide written informed consent (assent for minors); - Minors (6 to 17 years old) willing and able to provide a written assent, after obtaining written informed consent from their parents. Exclusion Criteria: - Being younger than 6 years old or weighing less than 20 kg; - Refusal to provide informed consent; - Previously treated for HAT (questionnaire to patients and/or family members); - Pregnant women. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Institute of Tropical Medicine, Belgium | Drugs for Neglected Diseases, Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, Ministry of Public Health, Democratic Republic of the Congo, SANRU Asbl, Soins de Santé Primaires en Milieu Rural, République Démocratique du Congo |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the feasibility of an alternative operational approach for the diagnosis and treatment of gHAT patients in areas with limited access and diagnostic capacities. | This qualitative study will assess:
Number of people with suggestive symptoms; Number of participants that test positive in the rapid diagnostic test; Number of sero-positive individuals who accept fexinidazole treatment and Number of treated individuals who test positive in further serological/molecular tests. |
11 months | |
Secondary | Assess gHAT transmission in the provinces of Maniema, Tanganyka and partially Lomami. | Based on the number of sero-positive individuals and confirmed infections, calculate gHAT incidence in the study areas. | 11 months | |
Secondary | Contribute to the collection of evidence of the use of fexinidazole. | The frequency and severity of any adverse effect due to the fexinidazole treatment will be recorded by a healthcare professional during the 10-day regime as well as in the 6-month follow-up visit. | 11 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01483170 -
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
|
Phase 1 | |
Terminated |
NCT00489658 -
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
|
Phase 2/Phase 3 | |
Completed |
NCT03087955 -
Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
|
Phase 2/Phase 3 | |
Completed |
NCT03025789 -
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
|
Phase 3 | |
Completed |
NCT02571062 -
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
|
Phase 1 | |
Terminated |
NCT00330148 -
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
|
Phase 3 | |
Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05947604 -
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
|
Phase 1 | |
Completed |
NCT01533961 -
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
|
Phase 1 | |
Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT00802594 -
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
|
Phase 2 | |
Completed |
NCT00146627 -
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
|
Phase 3 |